

EFFICACY OF RIFAPENTIN IN COMPLEX TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED LUNG TUBERCULOSIS

***S. O. Cherenko, N. A. Litvinenko,
L. M. Tsygancova, M. S. Kutishenko***

Summary

In open randomized controlled trial, which involved 40 patients with newly diagnosed lung tuberculosis, there were studied an efficacy and tolerability of rifapentin — long-acting rifampicin. Both rifapentin and rifampicin have equivalent efficacy in complex treatment of patients with newly diagnosed lung tuberculosis. Smear conversion was achieved in 94,1 % and 93,8 % patients, respectively. Rifapentin had good tolerability (equal to rifampicin). In 10 % of cases rifapentin caused transient elevation of ALT level, which did not require the withdrawal from the drug.